The Experts below are selected from a list of 2157 Experts worldwide ranked by ideXlab platform

Han Yaling - One of the best experts on this subject based on the ideXlab platform.

Zhang Quan-yu - One of the best experts on this subject based on the ideXlab platform.

Ghulam Murtaza - One of the best experts on this subject based on the ideXlab platform.

  • Development of in vitro-in vivo correlation for encapsulated Metoprolol Tartrate.
    Acta poloniae pharmaceutica, 2013
    Co-Authors: Abdulhakim A. A. Khaled, Khalid Pervaiz, Sabiha Karim, Kalsoom Farzana, Ghulam Murtaza
    Abstract:

    This study was aimed to develop level A, B and C in vitro-in vivo correlation (IVIVC) for encapsu- lated Metoprolol Tartrate (T1, T2 and T3 having Metoprolol Tartrate/polymer ratio of 1 : 1, 1 : 1.5 and 1 : 2, w/w). The in vitro data were correlated with in vivo data. For level A IVIVC, drug absorption data were calculated using Wagner-Nelson method. In addition, convolution approach was used to approximate plasma drug levels from in vitro dissolution data. The coefficient of determination (R 2 ) for level A IVIVC was 0.720, 0.905, 0.928 and 0.878 for Mepressor AE , T1, T2 and T3 formulations, respectively, with acceptable percent error (< 15%). The value of R 2 for level B and C IVIVC was 0.231 and 0.714, respectively. It is also concluded that level A IVIVC is a proficient mathematical model for biowaiver studies involving study parameters as those implemented for T1S (T1 formulation tested for dissolution in the presence of sodium lauryl sulfate) revealing that IVIVC level A is dosage form specific, rather than to be drug specific.

  • Metoprolol Tartrate-ethylcellulose tabletted microparticles: formulation and in vitro evaluation
    Latin American Journal of Pharmacy, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan
    Abstract:

    SUMMARY. This study introduced a novel phase separation technique for the microencapsulation of Metoprolol Tartrate as a model. Non-solvent addition coacervation technique was employed for the loading of drug into ethylcellulose, a hydrophobic plastic polymer. Dichloromethane (DCM) and paraffin oil were employed as solvent and non-solvent, respectively. Microparticle batches abbreviated as M1, M2 and M3 were formulated by embedding 1 g of drug into 1 g, 2 g and 3 g of polymer, respectively followed by direct compression into tabletted microparticulate batches named a T1, T2 and T3, respectively. The drug and polymer remained intact in encapsulated form as confirmed by FTIR, XRD and DSC. However, a slight change in drug nature from crystalline to amorphous behavior and an endothermic peak for Metoprolol Tartrate at 130 oC was observed in drug and microparticle thermograms. Slightly aggregated spherical free flowing microparticles in a size range of 64 ?m-103 ?m were obtained. The entrapment efficiency ranged from 77% to 89%. The straight line obtained from a plot between square root of time (Hrs) versus percent drug release (%) and regression co-efficient (R2) confirmed that best fit model to all dissolution profiles was Higuchi’s model. The modes of drug release from microparticles and tabletted microparticles were Quasi-Fickian diffusion and anomalous diffusion, respectively. T3 was selected as an optimum formulation as its dissolution profile resembled (f2 = 76.25) Mepressor® (Novartis Pharma-Pakistan). The accelerated stability study, regarding dissolution behavior and drug contents, at 40oC/75% RH proved T3 stable in 40 oC/75% RH for six months. Non-solvent addition coacervation technique involving comparatively safe solvents such as dichloromethane and paraffin oil as solvent and non-solvent, respectively is a good techniques for the encapsulation of Biopharmaceutics Classification System class I drugs such as Metoprolol Tartrate.

  • Metoprolol Tartrate ethylcellulose tabletted microparticles development of a validated invitro in vivo correlation
    World Academy of Science Engineering and Technology International Journal of Medical Health Biomedical Bioengineering and Pharmaceutical Engineering, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan, Sonia Khiljee, Muhammad Qamaruzzaman
    Abstract:

    Abstract — This study describes the methodology for the development of a validated in-vitro in-vivo correlation (IVIVC) for Metoprolol Tartrate modified release dosage forms with distinctive release rate characteristics. Modified release dosage forms were formulated by microencapsulation of Metoprolol Tartrate into different amounts of ethylcellulose by non-solvent addition technique. Then in-vitro and in-vivo studies were conducted to develop and validate level A IVIVC for Metoprolol Tartrate. The values of regression co-efficient (R 2 -values) for IVIVC of T2 and T3 formulations were not significantly (p<0.05) different from 1 while the values of R 2 for IVIVC of T1 and Mepressor ® were significantly (p<0.05) different from 1. Internal prediction errors of IVIVC, calculated from observed Area under Curve (AUC) and predicted AUC, were less than 10%. This study successfully presents a valid level A IVIVC for Metoprolol Tartrate modified dosage forms. Keywords — Metoprolol Tartrate, Dissolution, Bioavailability, Validated in-vitro in-vivo correlation.I.

  • Metoprolol Tartrate-Ethylcellulose Tabletted Microparticles: Development of a Validated Invitro In-vivo Correlation
    World Academy of Science Engineering and Technology International Journal of Medical Health Biomedical Bioengineering and Pharmaceutical Engineering, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan, Sonia Khiljee, Muhammad Qamar-uz-zaman
    Abstract:

    Abstract — This study describes the methodology for the development of a validated in-vitro in-vivo correlation (IVIVC) for Metoprolol Tartrate modified release dosage forms with distinctive release rate characteristics. Modified release dosage forms were formulated by microencapsulation of Metoprolol Tartrate into different amounts of ethylcellulose by non-solvent addition technique. Then in-vitro and in-vivo studies were conducted to develop and validate level A IVIVC for Metoprolol Tartrate. The values of regression co-efficient (R 2 -values) for IVIVC of T2 and T3 formulations were not significantly (p

  • Design, development and in-vitro evaluation of Metoprolol Tartrate tablets containing xanthan-tragacanth.
    Acta poloniae pharmaceutica, 2010
    Co-Authors: Akhtar Rasul, Ghulam Murtaza, Shujaat Ali Khan, Muhammad Hanif, Muhammad Javed Iqbal, Muhammad Waqas, Naveed S. Bhatti
    Abstract:

    The present study was undertaken to develop oral sustained release tablets of Metoprolol Tartrate using natural hydrophilic matrix formers (xanthan gum and tragacanth). Sustained release matrix tablets of Metoprolol Tartrate were prepared by using different ratios of drug, xanthan gum and tragacanth. Microcrystalline cellulose (MCC) was used as diluent. The polymer was incorporated into a matrix system using direct compression technique. All the lubricated formulations were compressed using concave punches in compression machine. Compressed tablets were evaluated for diameter, hardness, friability, weight variation and in vitro dissolution using USP dissolution apparatus-II. Different formulations were evaluated with respect to dissolution profile in 900 mL phosphate buffer (pH 6.8), 0.1 M HCl solution and distilled water for 12 h at 37 degrees C. Increasing the amount of polymer (xanthan gum) in the formulation led to slow release of drug and decreasing the amount of polymer gave enhanced release of Metoprolol Tartrate. The kinetic treatment showed the best fitted different mathematical models (Zero order, First order, Higuchi's and Hixson-Crowell). Most of the solid matrix formulations followed Higuchi or zero order kinetics. The formulations F1, F2, F3 and F7, F8, F9 showed maximum linearity while the formulations F4, F5, F6 were not of linear behavior. The results showed that the formulation F9 containing 30% xanthan gum and 10% gum tragacanth is the most similar to that of the reference marketed preparation.

Bistra Kostova - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of Poly(2-Ethyl-2-Oxazoline) Containing Copolymer Networks of Varied Composition as Sustained Metoprolol Tartrate Delivery Systems
    AAPS PharmSciTech, 2014
    Co-Authors: Bistra Kostova, Dimitar Rachev, Konstantin Balashev, Sijka Ivanova, Darinka Christova
    Abstract:

    Segmented copolymer networks (SCN) based on poly(2-ethyl-2-oxazoline) and containing 2-hydroxyethyl methacrylate, 2-hydroxypropyl acrylate, and/or methyl methacrylate segments have been evaluated as potential sustained release systems of the water soluble cardioselective β-blocker Metoprolol Tartrate. The structure and properties of the drug carriers were investigated by differential scanning calorimetry, attenuated total reflectance Fourier transform infrared spectroscopy, scanning electron microscopy, and atomic force microscopy. Swelling kinetics of SCNs in various media was followed, and the conditions for effective MT loading were specified. MT-loaded SCNs with drug content up to 80 wt.% were produced. The release kinetics of Metoprolol Tartrate from the systems was studied and it was shown that the conetworks of different structure and composition are able to sustain the Metoprolol Tartrate release without additional excipients.

  • Polyzwitterionic copolymer nanoparticles loaded in situ with Metoprolol Tartrate: synthesis, morphology and drug release properties
    Journal of Polymer Research, 2013
    Co-Authors: Bistra Kostova, Elena Kamenska, Dimitar Rachev, Silviya Simeonova, George Georgiev, Konstantin Balashev
    Abstract:

    Polyzwitterions belong to the “smart” polymers’ group because of their specific swelling properties which depend on pH and ionic strength of the aqueous media. Novel polyzwitterionic copolymer nanoparticles of vinyl acetate (VA) and 3-dimethyl(methacryloyloxyethyl)ammonium propane sulfonate (DMAPS) (p(VA-co-DMAPS)) with loaded in situ Metoprolol Tartrate were synthesized by emulsifier-free emulsion copolymerization in water. The influence of in situ addition of Metoprolol Tartrate on the emulsifier-free emulsion copolymerization mechanism was studied. It was suggested that the interactions between Metoprolol Tartrate and the copolymer nanoparticles are responsible for the creation of “bridge” connections between them and these bonds led to the formation of coagulum. To validate possible mechanisms of interaction between Metoprolol Tartrate and copolymer nanoparticles Differential Scanning Calorimetry was employed. Scanning Electron Microscopy, Atomic Force Microscopy, Dynamic Light Scattering and ζ-potential measurements were used to determine the average diameter, size distribution and ζ-potential of the copolymer nanoparticles. It was shown that the copolymer composition was an effective parameter for control of the release kinetics of in situ loaded Metoprolol Tartrate in copolymer nanoparticles.

  • synthesis and characterization of zwitterionic co polymers as matrices for sustained Metoprolol Tartrate delivery
    Journal of Biomaterials Science-polymer Edition, 2009
    Co-Authors: Elena Kamenska, Bistra Kostova, Dimitar Rachev, Ivo Ivanov, George Georgiev
    Abstract:

    Very stable co-polymer (vinyl acetate (VA)-co-3-dimethyl(methacryloyloxyethyl) ammonium propane sulfonate (DMAPS) (p(VA-co-DMAPS)) latexes with different compositions have been synthesized by emulsifier-free emulsion co-polymerization. The dry p(VA-co-DMAPS)s have been used in the preparation of drug tablets for sustained Metoprolol Tartrate release. It has been shown that the tablet swelling depends on the mol fraction of DMAPS monomer units (m DMAPS), pH and ionic strength (I). An original explanation, based on the swelling behavior of p(VA-co-DMAPS), has been proposed for the "overshooting" phenomenon observed. It assumes the formation of hydrophilic domains with a higher m DMAPS in the co-polymer tablets. The formation of dipole–dipole clusters between the DMAPS units at different m DMAPS and I are the main cause for the established differences in both the swelling kinetics of the p(VA-co-DMAPS) matrices and Metoprolol Tartrate release. The obtained results show that for p(VA-co-DMAPS) matrices-based ...

Shujaat Ali Khan - One of the best experts on this subject based on the ideXlab platform.

  • Metoprolol Tartrate-ethylcellulose tabletted microparticles: formulation and in vitro evaluation
    Latin American Journal of Pharmacy, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan
    Abstract:

    SUMMARY. This study introduced a novel phase separation technique for the microencapsulation of Metoprolol Tartrate as a model. Non-solvent addition coacervation technique was employed for the loading of drug into ethylcellulose, a hydrophobic plastic polymer. Dichloromethane (DCM) and paraffin oil were employed as solvent and non-solvent, respectively. Microparticle batches abbreviated as M1, M2 and M3 were formulated by embedding 1 g of drug into 1 g, 2 g and 3 g of polymer, respectively followed by direct compression into tabletted microparticulate batches named a T1, T2 and T3, respectively. The drug and polymer remained intact in encapsulated form as confirmed by FTIR, XRD and DSC. However, a slight change in drug nature from crystalline to amorphous behavior and an endothermic peak for Metoprolol Tartrate at 130 oC was observed in drug and microparticle thermograms. Slightly aggregated spherical free flowing microparticles in a size range of 64 ?m-103 ?m were obtained. The entrapment efficiency ranged from 77% to 89%. The straight line obtained from a plot between square root of time (Hrs) versus percent drug release (%) and regression co-efficient (R2) confirmed that best fit model to all dissolution profiles was Higuchi’s model. The modes of drug release from microparticles and tabletted microparticles were Quasi-Fickian diffusion and anomalous diffusion, respectively. T3 was selected as an optimum formulation as its dissolution profile resembled (f2 = 76.25) Mepressor® (Novartis Pharma-Pakistan). The accelerated stability study, regarding dissolution behavior and drug contents, at 40oC/75% RH proved T3 stable in 40 oC/75% RH for six months. Non-solvent addition coacervation technique involving comparatively safe solvents such as dichloromethane and paraffin oil as solvent and non-solvent, respectively is a good techniques for the encapsulation of Biopharmaceutics Classification System class I drugs such as Metoprolol Tartrate.

  • Metoprolol Tartrate ethylcellulose tabletted microparticles development of a validated invitro in vivo correlation
    World Academy of Science Engineering and Technology International Journal of Medical Health Biomedical Bioengineering and Pharmaceutical Engineering, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan, Sonia Khiljee, Muhammad Qamaruzzaman
    Abstract:

    Abstract — This study describes the methodology for the development of a validated in-vitro in-vivo correlation (IVIVC) for Metoprolol Tartrate modified release dosage forms with distinctive release rate characteristics. Modified release dosage forms were formulated by microencapsulation of Metoprolol Tartrate into different amounts of ethylcellulose by non-solvent addition technique. Then in-vitro and in-vivo studies were conducted to develop and validate level A IVIVC for Metoprolol Tartrate. The values of regression co-efficient (R 2 -values) for IVIVC of T2 and T3 formulations were not significantly (p<0.05) different from 1 while the values of R 2 for IVIVC of T1 and Mepressor ® were significantly (p<0.05) different from 1. Internal prediction errors of IVIVC, calculated from observed Area under Curve (AUC) and predicted AUC, were less than 10%. This study successfully presents a valid level A IVIVC for Metoprolol Tartrate modified dosage forms. Keywords — Metoprolol Tartrate, Dissolution, Bioavailability, Validated in-vitro in-vivo correlation.I.

  • Metoprolol Tartrate-Ethylcellulose Tabletted Microparticles: Development of a Validated Invitro In-vivo Correlation
    World Academy of Science Engineering and Technology International Journal of Medical Health Biomedical Bioengineering and Pharmaceutical Engineering, 2010
    Co-Authors: Fatima Rasool, Mahmood Ahmad, Ghulam Murtaza, Haji Muhammad Shoaib Khan, Shujaat Ali Khan, Sonia Khiljee, Muhammad Qamar-uz-zaman
    Abstract:

    Abstract — This study describes the methodology for the development of a validated in-vitro in-vivo correlation (IVIVC) for Metoprolol Tartrate modified release dosage forms with distinctive release rate characteristics. Modified release dosage forms were formulated by microencapsulation of Metoprolol Tartrate into different amounts of ethylcellulose by non-solvent addition technique. Then in-vitro and in-vivo studies were conducted to develop and validate level A IVIVC for Metoprolol Tartrate. The values of regression co-efficient (R 2 -values) for IVIVC of T2 and T3 formulations were not significantly (p

  • Design, development and in-vitro evaluation of Metoprolol Tartrate tablets containing xanthan-tragacanth.
    Acta poloniae pharmaceutica, 2010
    Co-Authors: Akhtar Rasul, Ghulam Murtaza, Shujaat Ali Khan, Muhammad Hanif, Muhammad Javed Iqbal, Muhammad Waqas, Naveed S. Bhatti
    Abstract:

    The present study was undertaken to develop oral sustained release tablets of Metoprolol Tartrate using natural hydrophilic matrix formers (xanthan gum and tragacanth). Sustained release matrix tablets of Metoprolol Tartrate were prepared by using different ratios of drug, xanthan gum and tragacanth. Microcrystalline cellulose (MCC) was used as diluent. The polymer was incorporated into a matrix system using direct compression technique. All the lubricated formulations were compressed using concave punches in compression machine. Compressed tablets were evaluated for diameter, hardness, friability, weight variation and in vitro dissolution using USP dissolution apparatus-II. Different formulations were evaluated with respect to dissolution profile in 900 mL phosphate buffer (pH 6.8), 0.1 M HCl solution and distilled water for 12 h at 37 degrees C. Increasing the amount of polymer (xanthan gum) in the formulation led to slow release of drug and decreasing the amount of polymer gave enhanced release of Metoprolol Tartrate. The kinetic treatment showed the best fitted different mathematical models (Zero order, First order, Higuchi's and Hixson-Crowell). Most of the solid matrix formulations followed Higuchi or zero order kinetics. The formulations F1, F2, F3 and F7, F8, F9 showed maximum linearity while the formulations F4, F5, F6 were not of linear behavior. The results showed that the formulation F9 containing 30% xanthan gum and 10% gum tragacanth is the most similar to that of the reference marketed preparation.